NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free AZTR Stock Alerts $0.19 -0.03 (-13.76%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$0.16▼$0.2350-Day Range N/A52-Week Range$0.16▼$5.18Volume1.71 million shsAverage Volume651,868 shsMarket Capitalization$5.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Azitra alerts: Email Address Azitra MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 7 Articles This WeekInsider TradingAcquiring Shares$115,476 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Azitra.Read more about Azitra's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.85% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently increased by 45.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAzitra does not currently pay a dividend.Dividend GrowthAzitra does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AZTR. Previous Next 3.1 News and Social Media Coverage News SentimentAzitra has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Azitra this week, compared to 0 articles on an average week.Search Interest2 people have searched for AZTR on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Azitra insiders have bought more of their company's stock than they have sold. Specifically, they have bought $115,476.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 11.16% of the stock of Azitra is held by institutions.Read more about Azitra's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioAzitra has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNew York goes dark, then America.Artificial intelligence is about to trigger a shocking new crisis in New York. Experts warn it could be “the next 9/11” and while New York will be ground zero for this looming catastrophe, it will not be the only state impacted. This crisis could affect 233 million Americans starting at any moment from now. Click here for the full story. About Azitra Stock (NYSEAMERICAN:AZTR)Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Read More AZTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AZTR Stock News HeadlinesMay 11 at 4:38 PM | markets.businessinsider.comOptimistic Outlook Justifies Buy Rating for Azitra Inc Amidst Promising Product Development and Strategic PartnershipsMay 11 at 3:52 AM | americanbankingnews.comAzitra (NYSEAMERICAN:AZTR) Shares Down 8% May 10 at 8:00 AM | businesswire.comAzitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual MeetingMay 9, 2024 | finance.yahoo.comAzitra, Inc. Announces Q1 2024 Financial Results and Provides Business UpdatesApril 22, 2024 | businesswire.comAzitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy MeetingApril 18, 2024 | businesswire.comAzitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024April 2, 2024 | finance.yahoo.comInsiders Are Buying These 11 Penny StocksApril 2, 2024 | benzinga.comSilo Pharma And 3 Other Stocks Under $5 Insiders Are BuyingMarch 15, 2024 | businesswire.comAzitra, Inc. Announces Full Year 2023 Financial Results and Provides Business UpdatesFebruary 16, 2024 | finance.yahoo.comAzitra, Inc. Announces Closing of Public OfferingFebruary 16, 2024 | businesswire.comAzitra, Inc. Announces Closing of Public OfferingFebruary 14, 2024 | benzinga.comDow Edges Higher; QuidelOrtho Shares PlummetFebruary 14, 2024 | benzinga.comNasdaq Gains 100 Points; Kraft Heinz Sales Miss ViewsFebruary 14, 2024 | nasdaq.comAzitra Prices Underwritten Public Offering Of 16.67 Mln Shares At $0.30/shr; Stock DropsFebruary 14, 2024 | msn.comWhy Azitra (AZTR) Shares Are Down 67%February 14, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Down 70% Today?February 14, 2024 | investorplace.comWhy Is Azitra (AZTR) Stock Down 70% Today?February 14, 2024 | finance.yahoo.comAzitra, Inc. Announces Pricing of Public OfferingFebruary 13, 2024 | businesswire.comAzitra, Inc. Announces Pricing of Public OfferingJanuary 19, 2024 | benzinga.comS&P 500 Gains 1%; State Street Reports Upbeat EarningsJanuary 17, 2024 | msn.comABAT, PRQR and SHOT among mid-day moversJanuary 16, 2024 | finance.yahoo.comAzitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the USNovember 15, 2023 | msn.comAzitra GAAP EPS of -$0.16, revenue of $0.31MNovember 14, 2023 | finance.yahoo.comAzitra, Inc. Announces Third Quarter 2023 Financial Results and Business UpdatesOctober 16, 2023 | finance.yahoo.comAzitra to Present at the ThinkEquity ConferenceSee More Headlines Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:AZTR CUSIPN/A CIKN/A Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual Sales$690,000.00 Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book0.83Miscellaneous Outstanding Shares28,810,000Free FloatN/AMarket Cap$5.75 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Francisco D. Salva (Age 53)President, CEO & Director Comp: $427.03kMr. Travis M. Whitfill M.P.H. (Age 34)Ph.D., Co-Founder, COO & Director Comp: $161.61kMr. Norman Staskey (Age 54)CFO, Treasurer & Secretary Comp: $314.02kDr. Mark SampsonChief Scientific OfficerKey CompetitorsKinetaNASDAQ:KAVirios TherapeuticsNASDAQ:VIRIShuttle PharmaceuticalsNASDAQ:SHPHHillstream BioPharmaNASDAQ:HILSHepion PharmaceuticalsNASDAQ:HEPAView All CompetitorsInsidersNorm StaskeyBought 47,600 shares on 3/29/2024Total: $9,996.00 ($0.21/share)Francisco D SalvaBought 333,300 shares on 2/13/2024Total: $99,990.00 ($0.30/share)Travis WhitfillBought 15,000 shares on 2/13/2024Total: $4,500.00 ($0.30/share)Norm StaskeyBought 3,300 shares on 2/13/2024Total: $990.00 ($0.30/share)Leslie W KreisBought 600,000 shares on 6/21/2023Total: $3 M ($5.00/share)View All Insider Transactions AZTR Stock Analysis - Frequently Asked Questions Are investors shorting Azitra? Azitra saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 296,200 shares, an increase of 45.6% from the April 15th total of 203,500 shares. Based on an average daily trading volume, of 836,900 shares, the short-interest ratio is currently 0.4 days. Approximately 1.9% of the shares of the stock are short sold. View Azitra's Short Interest. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.15) earnings per share for the quarter. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:AZTR) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressUrgent Nvidia WarningAltimetryProtect Your Bank Account Before It’s Too LateWeiss RatingsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
